In Alligator’s research projects, the company lays the foundation to continuously develop the pipeline of innovative drug candidates for tumor-directed immunotherapy. The company bases its research on its expertise within the TNF receptor superfamily (TNFRSF) and develops new mono- and bispecific antibodies in this field, internally as well as in collaboration with international biotech and pharma companies. In one of the research projects, a bispecific agonistic antibody that binds to a TNF receptor superfamily member and another target protein, is developed. The product components were generated using ALLIGATOR-GOLD® and FIND®, and merged using Alligator´s unique bispecific scaffold platform. This candidate will start pre-clinical development and cell line development for manufacturing of clinical material in 2018.